A Dose-Ranging Study of the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in COPD

Respiratory Research - United Kingdom
doi 10.1186/s12931-020-1307-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Inhaled Corticosteroids in Ventilated Preterm Neonates: A Non-Randomized Dose-Ranging Study

BMC Pediatrics
Child HealthPediatricsPerinatology
2018English

Stepwise Withdrawal of Inhaled Corticosteroids in COPD Patients Receiving Dual Bronchodilation: WISDOM Study Design and Rationale

Respiratory Medicine
PulmonaryRespiratory Medicine
2014English

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis

Rheumatology and Therapy
2014English

Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation

CPT: Pharmacometrics and Systems Pharmacology
ModelingSimulationCardiovascular MedicinePharmacologyCardiology
2019English

Stable COPD: Predicting Benefit From High-Dose Inhaled Corticosteroid Treatment

Yearbook of Medicine
2007English

Pharmacological Profile of GPD-1116, an Inhibitor of Phosphodiesterase 4

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2016English

Treatment of Diaphragmatic Fatigue With Inhaled Aminophylline Therapy in an Experimental Canine Model: An Open-Label, Dose-Ranging, Pharmacologic Study

Current Therapeutic Research
Pharmacology
2003English

A Case of Pityriasis Rubra Pilaris Treated Successfully With the Phosphodiesterase-4 Inhibitor Apremilast

Acta Dermato-Venereologica
DermatologyMedicine
2018English

Inhaled Corticosteroid Use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study

Lung
PulmonaryRespiratory Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy